三启生物

Sanqi Biotech is a biotechnology company based in Hangzhou, China, dedicated to the development of innovative gene editing therapies. The company leverages its proprietary base editing platforms, including Glycosylase Base Editors (GBE), to create precise treatments for genetic diseases and cancer. Their primary focus is on hematological disorders, with a lead program targeting beta-thalassemia through ex vivo gene-edited cell therapy. By utilizing base editing instead of traditional CRISPR-Cas9, Sanqi Biotech aims to minimize off-target effects and double-strand breaks, enhancing the safety profile of genetic medicines. The company is supported by prominent venture capital firms and maintains strong ties to leading academic research institutions in China.